Author Archives: Tom Hughes

This blog is written by Tom Hughes, CEO of Navitor Pharma, as part of the From The Trenches feature of LifeSciVC. We finally are beginning to understand the biological basis of aging and age-related diseases, making the discovery of new

Last week on February 28th – as I sat down to write this short blog– was Rare Disease Day 2015. Rare diseases, and there are estimated to be 7000 of them, impact almost 30 million people in the US alone, according to

That’s the dilemma facing drug hunters as leadership roles in biotech become more and more attractive.  You may have noticed that more and more seasoned pharma executives are making the move from big pharma or big biotech to lead small

Raising money is a huge part of being a CEO, but nothing can fully prepare you for the experience of taking your company public.   Together with our team at Zafgen, I recently had the experience of taking our company public

On January 9th, 2014, Intercept Pharmaceuticals (ICPT) released a very interesting piece of news regarding their Phase 2 FLINT (Farnesoid X Receptor Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis Treatment) trial.  FLINT, a test of their FXR agonist obeticholic acid (OCA)